Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sinopharm Group Co ( (HK:1099) ) has shared an update.
Sinopharm Group Co. Ltd. announced the successful conclusion of its 2024 annual general meeting and related shareholder meetings held on June 12, 2025. All proposed resolutions, including the approval of the company’s financial statements, profit distribution plan, and final dividend for 2024, were passed with significant majority votes. This outcome reflects strong shareholder support and positions the company favorably for continued growth and stability in the pharmaceutical sector.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, primarily engaged in the distribution and retail of pharmaceutical and healthcare products. The company focuses on providing comprehensive healthcare services and solutions, with a significant market presence in China.
Average Trading Volume: 7,869,082
Technical Sentiment Signal: Sell
Current Market Cap: HK$59.38B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.